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Abstract
Expression of human immunodeficiency virus type 1 (HIV-1) Gag protein in insect cells using baculovirus vectors leads to the abundant
production of virus-like particles (VLPs) that represent the immature form of the virus. When Gag-Pol is included, however, VLP production
is abolished, a result attributed to premature protease activation degrading the intracellular pool of Gag precursor before particle assembly
can occur. As large-scale synthesis of mature noninfectious VLPs would be useful, we have sought to control HIV protease activity in insect
cells to give a balance of Gag and Gag-Pol that is compatible with mature particle formation. We show here that intermediate levels of
protease activity in insect cells can be attained through site-directed mutagenesis of the protease and through antiprotease drug treatment.
However, despite Gag cleavage patterns that mimicked those seen in mammalian cells, VLP synthesis exhibited an essentially all-or-none
response in which VLP synthesis occurred but was immature or failed completely. Our data are consistent with a requirement for specific
cellular factors in addition to the correct ratio of Gag and Gag-Pol for assembly of mature retrovirus particles in heterologous cell types.
© 2003 Elsevier Science (USA). All rights reserved.
Introduction
An essential step in the morphogenesis of infectious
Human Immunodeficiency Virus Type 1 (HIV-1) is the
proteolytic maturation of immature viruses (Hoshikawa et
al., 1991; Kohl et al., 1988). Immature particles assemble on
the cytoplasmic face of the plasma membrane by oligomer-
ization of the viral structural protein Gag (p55) and the
co-incorporation of about 5% Gag-Pol. Maturation is
thought to occur during or shortly after the immature virus
particle buds from the host cell and is mediated by the
virion-encoded protease. Protease and the other viral enzy-
matic proteins are encoded by the pol domain and are
expressed as the Gag-Pol fusion protein via a 1 transla-
tional frameshift (Jacks et al., 1988). The level of frame-
shifting, approximately 5% of translation events, regulates
the expression of Pol and the enzymatic activities it con-
tains. During maturation, the protease cleaves Gag p55 into
four major proteins; matrix protein (p17), capsid protein
(p24), nucleocapsid protein (p7), and a proline-rich protein
(p6). Cleavage of Gag results in a structural rearrangement
of the particle, producing a central condensed conical capsid
core and a virion that is infectious (for reviews of HIV
assembly and maturation see Doms and Trono, 2000; Freed,
1998; Kra¨usslich, 1996).
The expression of Gag using heterologous expression
systems has been an important factor in understanding the
innate properties of Gag in the assembly of virus-like par-
ticles (Jones and Morikawa, 1998; Nermut et al., 1994;
Royer et al., 1991; Zhang et al., 1996). Using recombinant
baculoviruses, expression of Gag in insect cells results in
the assembly of virus-like particles (VLPs), which are mor-
phologically indistinguishable from immature particles as-
sembled in human cells (Gheysen et al., 1989; Jones and
Morikawa, 1998; Nermut et al., 1994). However coexpres-
sion of Gag with HIV-1 protease, either as part of the whole
pol domain or as a truncated version encoding only pro-
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tease, results in the abolition of VLP assembly (Gheysen et
al., 1989; Wagner et al., 1992). In mammalian cells, tight
regulation of protease activity is also essential for correct
virion morphogenesis as premature or accelerated proteo-
lytic processing prevents particle assembly (Hoshikawa et
al., 1991; Karacostas et al., 1993; Kra¨usslich, 1991, 1992;
Mergener et al., 1992). If protease activity is too low,
however, virus maturation is limited and virus infectivity is
reduced (Kaplan et al., 1993; Kohl et al., 1988; Kra¨usslich,
1992; Rose et al., 1995). In accordance with these observa-
tions, the failure of VLPs to assemble in insect cells in the
presence of protease has been proposed to be due to pro-
tease activity resulting in premature intracellular cleavage
of Gag (Gheysen et al., 1989; Wagner et al., 1992). Assem-
bly of HIV-1 VLPs in insect cells expressing Gag-Pol can
be rescued by inactivation of the protease, providing sup-
port for this proposal (Hughes et al., 1993). However, pur-
poseful modulation of protease activity at intermediate lev-
els similar to those required for the generation of mature
virions has not been previously investigated.
The ability to assemble mature HIV-1 VLPs using het-
erologous expression systems would greatly facilitate func-
tional studies into the poorly understood structural role (if
any) of Gag-Pol in virus assembly and the precise mecha-
nism of virus maturation. It would also provide a basis for
the production of high-titer infectious HIV-1 from a non-
mammalian cell background with potential safety advan-
tages for HIV-1-based gene delivery vectors (Kim et al.,
1998; Kotsopoulou et al., 2000). Here, we investigate the
consequence on VLP morphology of the expression of Gag-
Pol containing protease active site mutants that reduce in-
herent protease activity (Rose et al., 1995). We also mod-
ulate intracellular proteolytic activity within insect cells
expressing Gag-Pol through the addition of the HIV-1 pro-
tease inhibitor saquinavir (Roberts et al., 1990). We show
that while both of these strategies reduce intracellular pro-
tease activity in insect cells to levels normally associated
with virus maturation, neither strategy resulted in an inter-
mediate rate of proteolytic cleavage that was compatible
with the efficient assembly of mature VLPs.
Results
Expression of Gag-Pol containing T26S and A28S
protease mutations
Studies of the expression of HIV protease in mammalian
cells have shown that mutations T26S and A28S reduce
intrinsic catalytic activity by 4- and 50-fold, respectively
(Rose et al., 1995). A 4-fold reduction in activity resulted in
virions very similar to wild-type, with only a slight reduc-
tion in infectivity, while a 50-fold reduction in activity
resulted in immature noninfectious viruses (Rose et al.,
1995). As HIV protease activation appears excessive in
insect cells (Gheysen et al., 1989; Wagner et al., 1992), we
hypothesized that the expression of Gag-Pol incorporating
these two mutations in insect cells may result in an inter-
mediate rate of proteolysis compatible with VLP assembly
and maturation. Accordingly, recombinant baculoviruses
expressing HIV-1 Gag (AcGag), Gag-Pol (AcGag-Pol),
Gag-PolT26S (AcGag-PolT26S), and Gag-PolA28S (AcGag-
PolA28S) were constructed and their expression profiles were
evaluated by SDS–PAGE and Western blotting as described
(Fig. 1). Expression of Gag alone resulted in predominantly
uncleaved p55 precursor protein, while expression of wild-
type Gag-Pol resulted in extensive intracellular proteolytic
processing of Gag, with p24 capsid protein the predominant
protein detected (Fig. 1A, lanes 2 and 3). Expression of
Gag-PolT26S resulted in increased levels of Gag, while a
marginally less extensive intracellular proteolytic process-
ing was observed with the predominant protein product still
p24, but with detectable amounts of the processing inter-
mediate p41 and the uncleaved precursor p55 (Fig. 1A, lane
4). Expression of Gag-PolA28S, however, increased further
the level of Gag antigen, with significantly reduced intra-
cellular processing in insect cells with the predominant
bands Gag p55 and p41 (Fig. 1A, lane 5).
To assess the possibility that reduced protease activity
allowed rescue of VLP particle formation, the supernatant
fractions from recombinant baculovirus-infected cultures
expressing Gag-Pol was also analyzed (Fig. 1B). Confirm-
ing numerous reports, expression of Gag p55 led to abun-
dant Gag antigen in the supernatant of infected cells (Fig.
1B, lane 2), while expression of Gag-Pol showed no evi-
dence of Gag antigen release (Fig. 1B, lane 3). Expression
Fig. 1. Western blot analysis of Gag proteins expressed in Sf9 cells. Cell
lysates and supernatants were harvested and adjusted to an equivalent
protein concentration. Total loading of cellular extracts was 40 g of total
protein per lane except for AcGag, where the loading was reduced to 10
g. Similarly, while the supernatants were adjusted to 800-l equivalents
of infected cell media, the AcGag supernatant was 20-fold less to com-
pensate for an increased Gag signal. The samples analyzed were cells
infected with BacPAK6 (control) (lane1); AcGag (lane 2); AcGag-Pol
(lane 3); AcGag-PolT26S (lane 4); and AcGag-PolA28S (lane 5). Infected cell
lysates (A and C) or supernatants (B) were collected 48 h postinfection,
resolved by 12% SDS–PAGE, and Western blotted using anti-p24 antibody
(A and B) or anti-gp67 (C). The positions of uncleaved Gag p55, inter-
mediate p41, cleaved p24, and the baculovirus expression control gp67 are
indicated.
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of Gag-PolT26S also showed no evidence of Gag antigen
release (Fig. 1B, lane 4), although cell lysates showed weak
evidence of uncleaved and partially cleaved Gag antigen
(Fig. 1A). Expression of Gag-PolA28S, however, lead to
release of Gag p55 in the supernatant of infected cells,
although levels were lower than those by expression of Gag
only (Fig. 1B, lane 5). In addition, significant levels of Gag
p41 were present in supernatants from Gag-PolA28S-infected
cells. The differential Gag expression observed was not the
result of nonequivalent infection by any of the recombinant
baculoviruses as blotting with a monoclonal antibody to the
major baculovirus glycoprotein gp67 showed equivalent
infection by all recombinants (Fig. 1C).
These data are consistent with the reported mutant pro-
tease activities in mammalian cells (Rose et al., 1995) and
show that adjustment of protease activity through modifi-
cations in cis does allow intermediate levels of Gag proteo-
lytic processing in heterologous expression systems. Fur-
thermore, the reduction in activity associated with the
A28S, though not the T26S, mutation was sufficient to
rescue Gag release into the supernatant of expressing cells.
Nature of the Gag antigen secreted by expression of Gag-
PolA28S
The release of Gag antigen following expression of HIV
gag is the result of VLP assembly at the plasma membrane
(Boulanger and Jones, 1996; Gay et al., 1998; Gheysen et
al., 1989), a diagnostic for which is the sedimentation pro-
file of the antigen to band in sucrose gradients. Soluble Gag
antigen, as released by cell lysis, remains at the top of the
gradient (Royer et al., 1992). Accordingly, to assess the
nature of Gag antigen released by AcGag-PolA28S-infected
cells Gag antigen in the supernatant was collected by ultra-
centifugation and analyzed on a 20–60% sucrose velocity
gradient (Jowett et al., 1992). Following centrifugation, the
gradient was fractionated and analyzed by SDS–PAGE and
Western blotting. In addition, as AcGag-PolA28S encoded
the pol gene and there was evidence of Gag processing in
the supernatant of infected cells, peak fractions were also
tested for reverse transcriptase activity to assess the possi-
bility of copackaged Gag-Pol, a prerequisite for mature VLP
formation. Gag-reactive antigen expressed by AcGag was
detected in the middle fractions of the gradient, with a peak
at1.16 g/ml as reported (Jowett et al., 1992), whereas Gag
antigen expressed by AcGag-PolA28S exhibited a broader
band of reactivity, with the peak fraction marginally lighter
at around 1.13 g/ml (Figs. 2A and B). Such changes in
sedimentation rates have been previously associated with
aberrant particle synthesis by a variety of mutations, includ-
ing deletion of the p2 sequence (Jowett et al., 1992; Wang
et al., 1998) and matrix only particles (Giddings et al.,
1998), and would be consistent with particles of altered size
or composition. Reverse transcriptase assay of the peak
fractions from control, AcGag, and AcGag-PolA28S gradi-
ents revealed detectable RT activity associated with AcGag-
PolA28S, but not AcGag-infected cell supernatants (Fig. 2C).
However, concentration of the supernatant was required
before detection was possible and total activity equated to
10 mU/ml compared to a typical productive mammalian
vector system of 3000 mU/ml (e.g., see Kim et al., 1998).
These data suggest that modulation of HIV-1 protease
activity in insect cells, through mutation of the protease
active site, can lead to a change in the ratios of different Gag
cleavage products that is sufficient to rescue the expression
of Gag antigen into the supernatant of expressing cells.
However, the predominant secreted Gag band was at 55
kDa, the Gag precursor protein, there was no discernable
further processing by residual protease incorporated into the
VLPs, and the detected RT activity was very low. Thus, the
moderation of protease activity afforded by mutation A28S
Fig. 2. Sucrose gradient analysis and RT activity of VLPs assembled in Sf9
cells. VLPs present in the supernatant of infected Sf9 cells were sedimented
through a 20–60% step sucrose gradient (30K rpm, 1.5 h, 4°C, Beckman
SW41 rotor) in PBS. VLPs produced by AcGag (A) or AcGag-PolA28S (B)
were detected by 12% SDS–PAGE and Western blotting using anti-p24
antibody following gradient fractionation from the top. (C) Reverse tran-
scriptase activity detected in supernatants from cells infected with
BacPAK6 (control), AcGag, or AcGag-PolA28S is shown. The VLPs
present in 0.65 ml of infected cell supernatant were pelleted, resuspended
in 10 l of H20, and assayed using the Quant-T-RT kit, which utilizes the
scintillation proximity assay (SPA) principle to measure reverse transcrip-
tase activity by incorporation of [3H]TTP by reverse transcriptase into a
DNA/RNA primer/template bound to SPA beads (Amersham Pharmacia).
Purified recombinant HIV-reverse transcriptase (rHIV-RT, Amersham
Pharmacia) was used a positive control.
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was incompatible with the assembly of mature VLPs at a
level consistent with the intracellular Gag ratios observed.
A combination of protease mutation T26S and saquinavir
rescues the assembly of immature but not mature VLPs
While protease mutation A28S was sufficient to recover
Gag expression in the supernatant of expressing cells, pro-
tease activity was essentially inactivated. By contrast pro-
tease mutation T26S failed to recover Gag release of any
sort. This suggested that a protease activity between that
shown by A28S and T26S might accomplish Gag VLP
assembly and maturation in the baculovirus heterologous
expression system. To do this, the activity of the protease
inhibitor saquinavir on Gag processing by ProT26S in insect
cells was investigated. The addition of saquinavir over a
range from 10 to 0.001 M to insect cells infected with
wild-type AcGag-Pol inhibited intracellular Gag proteolytic
processing, as shown by decreased band intensity associated
with the cleaved p24 product, at levels similar to those
previously described (Overton et al., 1990) (Fig. 3A). How-
ever, no Gag antigen was detected in supernatants of ex-
pressing cells (not shown), suggesting that protease inhibi-
tion was insufficient to rescue Gag VLP assembly. Similar
concentrations of saquinavir also caused inhibition of Gag
processing in cells infected with AcGag-PolT26S (Fig. 3B)
but in this case Gag antigen was evident in the supernatant
of expressing cells at the higher saquinavir concentrations
(Fig. 3C, lanes 4–6), with the highest concentration (10
M) showing essentially only uncleaved Gag p55 (Fig. 3C,
lane 6). As the intermediate Gag processing observed in
AcGag-PolT26S-infected cells in the presence of 0.1–1 M
saquinavir resembled the pattern observed in HIV-infected
cells (Speck et al., 2000), electron microscopy was used to
assess the form of Gag released in the supernatant of ex-
pressing cells. VLP assembly with an immature morphol-
ogy typical of that produced by uncleaved p55 Gag was
observed in infected cells expressing Gag-Pol T26S supple-
mented with 10 M saquinavir (Figs. 4A and B), consistent
with the essential inhibition of protease activity. Some
VLPs with an immature morphology were also observed in
cells expressing Gag-PolT26S supplemented with 1 M sa-
quinavir (Fig. 4C) but the yield of VLPs was very low when
compared to the overall level of Gag antigen expression. No
VLPs were observed in cultures in the presence of 0.1 M
saquinavir despite the presence of cleaved Gag antigen in
the supernatant. In addition, cells expressing Gag-PolT26S in
the presence of 1 and 0.1 M saquinavir had an increased
level of cell disruption typical of the cytotoxicity associated
with cells expressing active HIV protease (Konvalinka et
al., 1995).
Discussion
Expression of the HIV gag and gag-pol genes in heter-
ologous expression systems was investigated as early as
1989 (Gheysen et al., 1989; Karacostas et al., 1989; Overton
et al., 1989). Expression of the HIV-1 gag gene in insect
cells led to the production of abundant VLP with an imma-
ture morphology, while expression of gag-pol abolished
VLP synthesis due to premature activation of the protease
(Gheysen et al., 1989), an explanation also supported by
later work linking particle assembly with protease activity
(Karacostas et al., 1993). The cytotoxicity of the protease
has also been suggested to play a role in the necessary
balance between Gag cleavage and cell integrity needed for
the formation of budded particles that are able to mature
(Konvalinka et al., 1995). Stable expression of single copy
HIV gag-pol in human cell lines or expression of the struc-
tural proteins through plasmid-based transfection results in
the production of mature retrovirus particles (Kim et al.,
1998; Wang et al., 1999), suggesting that no other viral
factor is required. Thus, baculovirus expression of Gag and
Gag-Pol at levels that mimic the level of Gag cleavage
observed during human cell expression should give rise to
virion particles with a mature phenotype. We used site-
directed mutagenesis of the HIV protease within a gag-pol
cassette to modify HIV protease activity to investigate an
intermediate level low enough to allow virus particle as-
sembly but with sufficient residual activity to carry out
particle maturation inside the assembled VLP.
Baculovirus expression of Gag-Pol encoding protease
active site mutations T26S and A28S (Rose et al., 1995)
showed that mutation T26S had a marginal effect on the
Gag cleavage pattern, while A28S significantly reduced
Fig. 3. Expression of Gag proteins in the presence of saquinavir. Gag
proteins expressed in Sf9 cells infected with recombinant baculoviruses
expressing AcGag-Pol (A) and AcGag-PolT26S (B and C) and treated with
the protease inhibitor saquinavir are shown: lane 1, no drug; lanes 2–6,
10-fold increases in drug concentration from 0.001 to 10 M, respectively.
(A and B) Shown are cell lysates harvested 48 h postinfection, while C
represents soluble protein (800 l of supernatant). Protein samples were
separated by 12% SDS–PAGE and followed by Western blotting using
anti-Gag-p24 antibody. The positions of uncleaved Gag p55, the partial
Gag cleavage intermediate p41, and cleaved p24 are indicated.
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proteolytic processing to a level similar to that observed
when Gag alone is expressed (i.e., to a level where only
proteolysis by cellular proteases is observed (Jowett et al.,
1992)). In addition, overall levels of Gag antigen were
higher when protease activity was reduced, reflecting the
reduced cytotoxicity, due to loss of nuclear integrity and
proteolytic cleavage of host cytoskeletal cell proteins, nor-
mally observed following expression of active HIV-1 pro-
tease (Konvalinka et al., 1995; Kra¨usslich, 1991). VLP
synthesis following expression of Gag-PolA28S, but not
Gag-PolT26S, reflected the levels of precursor p55 protein
present in cells and the morphology was immature, although
Fig. 4. Electron microscopy of assembled VLPs. Representative thin section electron micrographs of HIV VLPs assembled in Sf 9 cells infected with
AcGag-PolT26S and treated with saquinavir at 10 M (A and B) and 1 M (C). All the VLPs examined had a morphology typical of immature viruses.
Rod-shaped baculoviruses are also present in A. Bars is 100 nm.
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slight sedimentation differences on sucrose gradients could
have been due to altered particle composition or size when
compared to Gag-only-derived VLPs.
The expression of Gag-PolT26S did not lead to the rescue
of VLP synthesis but the addition of the protease inhibitor
saquinavir caused a reduction in the level of intracellular
Gag processing to a level that rescued the assembly of
particles, as shown by Gag antigen in the supernatant of
infected cells and evidence of VLPs by electron micro-
scopy. VLPs were only formed at saquinavir concentrations
that essentially inhibited protease activity completely, re-
sulting in high amounts of Gag p55 and an immature VLP
morphology. Intermediate levels of saquinavir produced a
level of Gag intracellular cleavage that was similar to the
cleavage patterns seen in HIV-infected cells yet produced a
very low level of particles, all with immature morphology.
We cannot rule out that our strategy of partial protease
activity results in small numbers of mature VLPs (0.1% of
total VLPs based on examined EMs) but in this case their
assembly efficiency does not reflect the level of intracellular
Gag cleavage products observed. These data therefore do
not support a mechanism of VLP assembly that requires
only the correct ratios of Gag and Gag-Pol, as inferred from
studies in mammalian cells (Karacostas et al., 1993).
Two models can be envisaged for the failure of suitable
ratios of Gag and Gag-Pol to produce mature VLP. In the
first, a selection mechanism operates at the level of assem-
bly in which only uncleaved molecules enter the VLP as-
sembly pathway and that Gag-Pol molecules, even with a
protease activity appropriately modified to prevent prema-
ture cleavage, are either excluded or included in an inactive
state. In the second, no distinction is made between Gag and
Gag-Pol molecules, but premature activity by the protease
results in particle collapse and only uncleaved Gag-Pols, by
default, complete the assembly and budding pathway. Our
data do not discriminate clearly between these possibilities
but the fact that no graded response in VLP release between
immature and mature phenotypes is seen argues in support
of the former model rather than the latter. Recently, host
factors, specific to human cells, have been found to be
involved in the assembly and budding of HIV (Demirov et
al., 2002; Garrus et al., 2001; Martin-Serrano et al., 2001;
VerPlank et al., 2001; Zimmerman et al., 2002). These
factors have been shown to be involved in the trafficking
and budding of virus more than in budding and maturation
per se (Perez and Nolan, 2001). In our experiments budding
of immature VLPs was very efficient, indicating no alter-
ation in Gag trafficking, but when budding was combined
with an active protease, particle assembly adopted an ei-
ther/or pathway of VLP assembly or non assembly. These
data suggest that host cell factors, including those above,
may have a role in sorting the correct Gag and Gag-Pol
ratios or creating a microenvironment necessary for the
development of a particle that is, first, competent for assem-
bly and, second, capable of onward maturation. A link
between virus release and the initiation of protease action
has been previously reported but the molecular basis of the
interaction was ill-defined (Kaplan et al., 1994). A link
between budding and maturation has been also shown
through the use of proteasome inhibitors that have no direct
effect on the viral protease, yet inhibit both processes (Schu-
bert et al., 2000). Last, lack of a chaperone activity specific
for protease containing Gag molecules has been suggested
to be the cause of the failure to assemble RSV VLPs in
insect cells (Johnson et al., 2001), suggesting that all retro-
viruses may share a similar requirement.
Our data would be consistent with the fact that there is an
intricate yet ill-defined step in the retrovirus assembly path-
way that demands host involvement only when an active
viral protease is present. Producing VLPs that are able to
mature, for structural study or use as gene vectors, from
heterologous cells will require a precise definition of this
step.
Materials and methods
Recombinant baculoviruses and cell culture
All recombinant baculoviruses produced were derived
from Autographa californica multiple nuclear polyhedrosis
virus. The baculoviruses were generated by cotransfecting
Spodoptera frugiperda (Sf 9) cells with recombinant trans-
fer vector and linear BacPAK6 viral DNA (Clontech). Cell
supernatants, harvested after 5 days, were plaque assayed
and plaques picked and grown for virus stocks as described
(King and Possee, 1992). Recombinant baculoviruses were
confirmed by the immunodectection of Gag at 2 days
postinfection (pi). Serum-free adapted Sf 9 cells were prop-
agated at 28°C as described (O’Reilly et al., 1992), except
that Sf-900 II medium (GibcoBRL, Life Technologies) was
used throughout.
Construction of recombinant transfer vectors
To produce the recombinant transfer vector expressing
HIV-1 Gag-Pol, the gag-pol gene was amplified from
HIV-1 proviral clone strain HXB2 (AIDS reagent repository
(Holmes, 2000)) by the polymerase chain reaction using the
following primers (NotI linkers underlined): 5-GGCGCG-
GCCGCATGGGTGCGAGAGCGTCGG-3 and 3-GTTC-
ATCTGTCCTACTCCTAATTCGCCGGCGCGG-5.
The amplified product was cloned into the NotI restric-
tion site of the baculovirus transfer vector pBAC4x-1 (Cam-
bridge Bioscience), placing the gene under the control of a
polyhedrin promoter and the entire gag-pol coding region
was verified by sequencing prior to expression studies.
Mutations Thr263Ser (T26S) and Ala283Ser (A28S)
were introduced into the protease active site using the Quick
Change Site-Direct Mutagenesis kit (Stratagene) using the
mutagenic primers 5-CTAAAGGAAGCTCTATTAGAT-
TCTGGAGCAGATGATACAGTATTAG-3 (T26S) and
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5-GAAGCTCTATTAGATACAGGATCCGATGATACA-
GTATTAGAAGAAA TG-3 (A28S). Clones containing
the correct mutations were confirmed by DNA sequencing.
Expression and preparation of proteins
Monolayers of Sf 9 cells were infected with baculovirus
as described (King and Possee, 1992) using a multiplicity of
infection (m.o.i) of 5 and harvested 48 h pi. Cell lysates
were prepared by resuspension in cell lysis buffer (1 PBS,
1% v/v NP-40) for 20 min at 4°C followed by clarification
at 4K rpm for 10 min at 4°C. Protein concentrations were
determined using a commercial protein assay kit (Bio–Rad).
Isolation and purification of virus-like particles
VLPs present in the supernatant of infected insect cells
were collected by centrifugation at 24K rpm for 1 h at 4°C
in a SW28 rotor (Beckman). The pellet was resuspended in
PBS and loaded onto a 20–60% step sucrose gradient that
had been allowed to stand overnight at 4°C before use and
centrifuged for 1.5 h at 30K rpm, 4°C, in a SW41 rotor
(Beckman). Fractions were collected from the top and a
10-l aliquot of each fraction was analyzed by SDS–PAGE
and Western blot. Fraction density, as a measure of sedi-
mentation, not particle density at equilibrium, was measured
by weight.
SDS–PAGE and Western blotting
Protein samples were prepared in Laemmli sample buffer
(Laemmli, 1970), separated by 12% SDS–PAGE, and visu-
alized by staining with Coomassie brilliant blue. For West-
ern blots, proteins were transferred to PVDF membranes
(Immobilon-P, Millipore) and blocked for 1 h at room
temperature in PBS containing 0.1% Tween 20 (PBS-T) and
5% milk powder. Incubation with anti-HIV-1 Gag p24 an-
tibody (Aalto BioReagents, Dublin at 1:1000 dilution) was
for 1 h at room temperature followed by washing several
times with PBS-T. Membranes were incubated for a further
1 h with peroxidase-conjugated donkey antisheep antibody
(Sigma) and bound antibodies were detected by chemilumi-
nescence (Roche).
Treatment with the protease inhibitor saquinavir
The antiprotease drug saquinavir (Ro 31-8959, Roche)
was prepared as a 10 mM stock solution in methanol and
stored at 80°C. Following infection of Sf 9 cells with a
Gag-Pol expressing baculovirus, drug was added to the cell
media at concentrations ranging from 0.001 to 10 M and
expression profiles were analyzed by SDS–PAGE and
Western blot as before.
Electron microscopy
The procedure followed was that described by Jowett et
al., (1992). Briefly, infected cells dislodged by gentle tap-
ping were collected by low-speed centrifugation at 1K rpm
for 5 min at 21°C. The cells were resuspended in 0.1 M
sodium cacodylate buffer, pH 7.4, containing 1% v/v glu-
taraldehyde (25% EM grade). Following fixation the cells
were embedded in Araldite, sectioned, and poststained with
uranyl acetate as described (Hockley et al., 1988). Speci-
mens were examined using a Philips CM12 electron micro-
scope operating at 80 kV.
Reverse transcription assay
Particles in the supernatants from infected Sf cells were
concentrated by sedimentation as described and reverse
transcriptase activity was assessed using the Quant-T-RT kit
(Amersham Pharmacia). Purified HIV-1 reverse transcrip-
tase at 1, 10, and 100 mU/ml, which gave an activity
linearly related to dose, was used as a positive control. Only
the positive sample approximating the activity found in the
tests was included in the data shown.
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